1. Five drugs, including two from Novartis, win EMA endorsement —What’s next for Amarin’s stock after FDA panel recommendation — Shionogi antibiotic scores FDA ok— See more on our front page news

    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

after cuts, still poor RD management

Discussion in 'Merck Lab Personnel' started by Anonymous, Jan 7, 2014 at 4:10 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    few good leaders and decision makers. keeping managers who pushed 5S? so many cuts difficult for projects to move foward. too many under achiever managers in WP with little discovery experience
  2. Anonymous

    Anonymous Guest

    What do you expect from a "pharmaceutical" company that doesn't have scientists in its upper management? Merck has top-down problems. Don't expect reorganization to change the direction of a company that has no direction to begin with. Shareholders have their head buried in the sand, IMO.
  3. Anonymous

    Anonymous Guest

    I only buy other pharma stocks. Management needs replacement. Few have pushed product to market. WP has too many executive levels with 2 page resumes. Roger make the changes.